Form 4 · Filed Jul 30, 2026, 01:00 AM UTC
ROIV/Roivant Sciences Ltd.
Venker Eric — President & Immunovant CEO
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
3 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | M | other | 200,000 | $4 | $770,000 | 1,813,063 |
| Jul 27, 2026 | S | sell | 200,000 | $35 | $6,990,000 | 1,613,063 |
| Jul 27, 2026 | M | other | 200,000 | — | — | 4,044,834 |
Source: SEC EDGAR raw filing ↗ · Accession 0001140361-26-030107